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Weight loss for overweight and obese individuals 
with gout: a systematic review of longitudinal studies
Sabrina M nielsen,1 Else M Bartels,1 Marius Henriksen,1,2 Eva E Wæhrens,1,3 
Henrik Gudbergsen,1 Henning Bliddal,1 Arne Astrup,4 Filip K Knop,5,6,7 
Loreto Carmona,8 William J taylor,9 Jasvinder A Singh,10 Fernando perez-ruiz,11 
Lars E Kristensen,1 robin Christensen1
AbstrACt
Objectives Weight loss is commonly recommended 
for gout, but the magnitude of the effect has not 
been evaluated in a systematic review. the aim of this 
systematic review was to determine benefits and harms 
associated with weight loss in overweight and obese 
patients with gout.
Methods We searched six databases for longitudinal 
studies, reporting the effect of weight loss in overweight/
obese gout patients. risk of bias was assessed using 
the tool risk of Bias in non-randomised Studies of 
Interventions. the quality of evidence was assessed 
using the Grading of recommendations Assessment, 
development and Evaluation.
results From 3991 potentially eligible studies, 10 were 
included (including one randomised trial). Interventions 
included diet with/without physical activity, bariatric 
surgery, diuretics, metformin or no intervention. Mean 
weight losses ranged from 3 kg to 34 kg. Clinical 
heterogeneity in study characteristics precluded meta-
analysis. the effect on serum uric acid (sUA) ranged from 
−168 to 30 μmol/L, and 0%–60% patients achieving 
sUA target (<360 μmol/L). Six out of eight studies (75%) 
showed beneficial effects on gout attacks. two studies 
indicated dose–response relationship for sUA, achieving 
sUA target and gout attacks. At short term, temporary 
increased sUA and gout attacks tended to occur after 
bariatric surgery.
Conclusions the available evidence is in favour of 
weight loss for overweight/obese gout patients, with 
low, moderate and low quality of evidence for effects on 
sUA, achieving sUA target and gout attacks, respectively. 
At short term, unfavourable effects may occur. Since 
the current evidence consists of a few studies (mostly 
observational) of low methodological quality, there is 
an urgent need to initiate rigorous prospective studies 
(preferably randomised controlled trials).
systematic review registration proSpEro, 
Crd42016037937.
IntrOduCtIOn
Gout is a common form of inflammatory arthritis,1 2 
with an age-standardised global prevalence of 0.08% 
and is higher in developed countries.3 Gout is a 
crystal-deposition disease resulting from chronic 
elevation of serum uric acid (sUA) above the satura-
tion point for monosodium urate (MSU).4–7 Initial 
presentation is severely painful episodes of periph-
eral joint synovitis (acute ‘attacks’), but joint damage 
and subcutaneous tophus deposition may develop.8 
The general management principle is to reduce sUA 
levels, allowing MSU crystals to dissolve, leading to 
the elimination of acute attacks, disappearance of 
tophi and possibly cure of the disease.9–11
Body mass index (BMI) is strongly positively 
correlated to sUA levels,12 13 and weight loss is a 
commonly recommended treatment for gout.14–23 
Furthermore, weight loss from bariatric surgery 
is associated with reduced incidence of hyper-
uricaemia and gout.24 The mechanism by which 
weight loss can lower sUA levels is poorly under-
stood. Some suggest that improved insulin resis-
tance results in less insulin-enhanced reabsorption 
of organic anions such as urate,2 and a study 
demonstrated decreased sUA in overweight patients 
receiving either weight loss from low-energy diet 
or an insulin-sensitising agent.25 However, a study 
of severe obese patients receiving bariatric surgery 
found no association between reduced sUA levels 
and improved insulin resistance,26 making a rela-
tionship questionable.
Guidelines recommending weight loss for gout 
patients14–23 are based on evidence from only few 
clinical studies,27 28 one population-based study29 
and indirect evidence from studies on non-gout 
subjects. The evidence for effectiveness in clinical 
studies has to our knowledge not previously been 
evaluated in a systematic review. Therefore, the 
primary objective of this systematic review was to 
determine the benefits and harms associated with 
weight loss in overweight and obese individuals 
with gout. Furthermore, we had an explicit focus 
on the weight loss intervention (including magni-
tude and intensity) to see whether a dose–response 
relationship exists at the study (ie, group) level.
MethOds
Protocol
A protocol adhering to the Preferred Reporting 
Items for Systematic review and Meta-Analysis 
Protocols 2015 statement30 was registered online 
(PROSPERO: CRD42016037937) and published 
on www. parkerinst. dk.
search strategy
We searched four bibliographic databases on 26 
April 2016; MEDLINE via Ovid from 1946, 
EMBASE via Ovid from 1974, Web of Science via 
Web of Knowledge from 1900, Cochrane Central 
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Register of Controlled Trials (CENTRAL, The Cochrane Library), 
as well as  ClinicalTrials. gov and WHO International Clinical 
Trial Registry Platform portal (search strategy presented: online 
supplementary text S1). We screened reference lists of relevant 
articles, as well as the American College of Rheumatology (ACR) 
and European League Against Rheumatism conference abstracts 
from 2014 and 2015, the ACR conference abstracts from 2016 
and content experts were asked if they were aware of any other 
relevant studies.
study selection
Anticipating only few randomised controlled trials (RCTs), we 
also included longitudinal observational studies (non-randomised 
studies) that quantitatively estimated the effect following weight 
loss. Studies needed to include ≥10 adult and overweight/obese 
patients (author described or BMI ≥25 kg/m231) with diagnosed 
gout (author described or meeting the 1977 ACR criteria for 
gout32). Eligible interventions included those where a weight 
reduction was reported explicitly, whether intentional or unin-
tentional. The weight reduction was required to be the only 
difference in terms of intervention from the defined control 
group. Two reviewers (SMN supported by EMB) assessed the 
records. Disagreements were resolved by consensus or by discus-
sion with a third reviewer (RC).
data extraction and management
Two reviewers (SMN supported by RC) extracted the data. 
Prespecified outcomes included essential outcome domains for 
chronic gout33 34: (1) joint pain; (2) tophus/tophi; (3) physical 
function; (4) health-related quality of life (HRQoL); (5) sUA 
change; (6) Achieving sUA target (ie, sUA reduction to <360 
μmol/L (6 mg/dL)); (7) serious adverse events (SAEs, defined as 
adverse events that are fatal, life-threatening or require hospital-
isation); (8) withdrawals due to adverse events (WDdtAEs); (9) 
patient global assessment; (10) wody weight change; and (11) 
gout attacks (any measure).
Assessment of risk of bias in included studies (internal 
validity)
Two reviewers (SMN supported by RC) assessed risk of bias 
using the tool Risk of Bias In Non-Randomised Studies of Inter-
ventions35 36 for evaluation of the risk of bias in non-randomised 
studies comparing health effects of two or more interventions. 
Figure 1 PRISMA flow diagram. Modified from Moher et al.75 pts, patients.
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Post hoc, we decided to also use this tool for assessing studies 
with only one study group, by assuming that a virtual control 
group not receiving any intervention and experiencing no effect 
on any outcome was available, and for assessing RCTs, making 
comparisons possible. We resolved disagreements by discussion.
Important confounders of interest and cointerventions 
possibly affecting the effect of weight loss were not specified 
at protocol stage but prior to the risk of bias assessment (online 
supplementary text S2).
Reporting bias in individual studies was further investigated 
by comparing the constructed outcome reporting matrix,37 with 
the protocols (if available).
statistical analyses and evidence synthesis
None of our planned meta-analyses were conducted due to indis-
putable clinical heterogeneity in study characteristics (PICOTs). 
Instead it was decided post hoc that data for each study would 
be presented for all time points in a summary of findings table 
and the latest time point as changes from baseline would be 
summarised for each study in a summary of findings and GRADE 
evidence profile table. Based on the tables, we qualitatively 
considered the impact of follow-up time, that is, short-term (<3 
months), medium (3–12 months) and long-term (>12 months), 
acute versus chronic gout, presence versus absence of concur-
rent urate-lowering medication use, presence versus absence of 
tophi, the dose–response phenomena of weight loss in magni-
tude and intensity (ie, magnitude over time) and the impact of 
bias. A graph showing the relationship between weight loss and 
sUA was constructed post hoc.
dealing with missing data
Where data were missing or incomplete, we searched for infor-
mation from the study authors and from additional records for 
the study. No imputations were carried out for patients lost at 
follow-up. Missing body weights were estimated from BMI, 
assuming a height of 1.70 m. Missing SDs were calculated from 
other statistics such as standard errors, or estimated from other 
studies investigating gout patients; for sUA, we used a SD for 
change from baseline of 137 μmol/L.
Assessing the quality of the evidence
We assessed the quality of the evidence with the GRADE 
approach,38 starting at low quality of evidence, since the evidence 
was primarily based on observational studies and subsequently 
down-rated or up-rated the evidence.
results
study selection
We identified 3991 records after removal of duplicates, 
forwarding 456 for full-text assessments after screening 
(figure 1). After excluding 442 records (see online supplemen-
tary text S3), we identified 14 records describing 10 studies for 
inclusion in the systematic review.27–29 39–49
During the study selection and data extraction, authors of 18 
studies27–29 40 43–46 49–58 were contacted; three responded27 44 45 
and provided additional information, including unpublished data 
for Perez-Ruiz et al.45
study characteristics
The studies were comprised of one RCT49 and nine non-ran-
domised studies (table 1). Gout patients were a subgroup in three 
of the studies,27 29 44 of which one study initially only included 
non-gout patients but did a subanalysis on recurrent gout attacks 
for those who developed gout during follow-up.44 The studies 
included between 12 and 408 gout patients, including 0%–75% 
females. The average age and BMI ranged from 49 to 63.3 
years, and 26.0 to 49.6 kg/m2, respectively. Case definitions of 
gout included the use of the 1977 ACR criteria in one study,42 
diagnosis confirmed by detecting crystals in three studies,28 40 45 
asking ‘Have you been told by your physician that you have 
gout?’ in two studies,29 44 medical history and documentation 
of previous gout attacks in one study,43 documented episode(s) 
or evidence of medication use in one study,46 or not specified 
in two studies41 49 (online supplementary table S1). Comor-
bidities selected in the studies, besides overweight, included 
type 2 diabetes,27 hypertension41 and a high cardiovascular risk 
profile.29 44
Interventions included intentional weight loss from dietary 
changes with or without increased physical activity,27 28 bariatric 
surgery27 43 46 and unintentional weight loss from high protein 
diet,49 diuretics41 and metformin.40 Three studies29 44 45 stratified 
according to weight or BMI reduction, using no reduction as 
control. Four studies had no control group.27 28 40 43 Follow-up 
ranged from 4 weeks to 7 years, and a mean weight loss of 
3–34 kg at latest follow-up was reported.
effect of weight loss
No data were available for joint pain, HRQoL or patient global 
assessment (outcome matrix: online supplementary table S2). 
One study45 provided data on tophi, reporting none for both 
groups at baseline and follow-up, and one study27 provided data 
on physical function measured by Short Form-36 physical func-
tioning domain, reporting diminished function with the values 
43.3 (SD 21.8), 24.6 (SD 28.2), 10.8 (SD 12.8) at baseline, 6 
months and 1.5 years, respectively. One study40 reported four 
WDdtAEs from metformin, and one study27 did not report any 
SAEs in gout patients. On sUA, achieving sUA target and gout 
attacks, eight, five, and eight studies provided data, respectively 
(table 2).
The effect on mean sUA ranged from −168 μmol/L to 30 
μmol/L (−2.8 mg/dL to 0.5 mg/dL) at latest follow-up (table 3). 
Studies with the largest (and fastest) weight loss showed in 
general the largest decrease (figure 2).27 28 46 Furthermore, a 
dose–response relationship was shown by Zhu et al29 with a 
weight loss of ≥10 kg being associated with a change in sUA of 
−37 μmol/L. It should be noted that non-gout and non-over-
weight patients were included in their analysis as well. At short 
term, Dalbeth et al (part 2)27 reported an immediate postoper-
ative mean sUA of 510 (SD 130) μmol/L, that is, an increase of 
70 μmol/L from bariatric surgery, and at latest follow-up, sUA 
had dropped to 330 (SD 90) μmol/L. In that period, three out 
of seven patients terminated urate-lowering medication, that is, 
the decrease may truly be larger. Three studies showed no effect 
on sUA; Perez-Ruiz et al45 and Dalbeth et al (part 1),27 both 
with a concurrent decrease in urate-lowering medication, and 
Brandstetter et al,41 where the weight loss may partly be due 
to diuretics and hence truly lower. Barskova et al40 showed a 
decrease in sUA from a weight loss of only 3 kg. However, the 
use of metformin can have affected the results.
The proportion achieving sUA target (<360 μmol/L) ranged 
from 0% to 60% reduction in patients with raised sUA. Further-
more, a dose–response relationship was shown by Zhu et al29 
with approximately three times higher odds of achieving sUA 
target with loss of ≥10 kg body weight during 7 years compared 
with not losing weight. It should be noted that non-overweight 
gout patients were included in their analysis as well. The 0% and 
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1% reduction in patients with raised sUA reported by Dalbeth 
et al (part 1)27 and Perez-Ruiz et al,45 respectively, are consis-
tent with no change in sUA. Furthermore, achieving sUA target 
reported by Dessein et al28 may be overestimated due to using a 
higher sUA cut-off of 510 μmol/L.
All studies, except two,27 43 with data on gout attacks, showed a 
beneficial effect, and Dessein et al28 reported 71% fewer attacks. 
Furthermore, a dose–response relationship was shown by Nguyen 
et al.44 It should be noted that non-overweight patients were 
included in their analysis as well. Dalbeth et al (part 2)27 reported 
an increase from zero patients experiencing ≥1 attack during 
6 months to three patients during 12 months. This is possibly 
due to including the immediate postoperative phase where 
attacks could be a consequence of the increased sUA. Likewise, 
Romero-Talamás et al46 report a possible increase from 24% expe-
riencing ≥1 attack during 1 year at baseline to 18% during 1 month 
at 1-month follow-up, and a subsequently decrease to 8% during 
1 year at last follow-up.
Only one study40 included patients with tophi at baseline, 
therefore the impact on tophi could not be assessed.
risk of bias assessment
The most frequent risk of bias was ‘Bias due to confounding’, 
with four studies rated critical due to studying one group without 
adjustment for confounders.28 40 42 43 Five studies were rated serious 
(figure 3), and only the RCT49 was rated low risk of bias. All studies 
were rated serious risk for ‘Bias due to departures from intended 
interventions’ (see possible confounders and cointerventions in 
online supplementary table S3). Reporting bias was suspected 
for two studies reporting change in BMI instead of change in 
weight.40 46 Protocols were only found for two substudies29 44 
of one main study39 47 and three studies reported no published 
protocol.27 44 45
Quality of the evidence using GrAde
For a beneficial effect of weight loss at medium-term/long-term 
follow-up, we evaluated the overall quality of evidence to be low 
for sUA, moderate for achieving sUA target and low for gout attacks.
dIsCussIOn
Overall, we found low to moderate quality of evidence for 
beneficial effects of weight loss for overweight gout patients in 
terms of sUA, achieving sUA target and gout attacks. No or few 
data were available on our remaining prespecified outcomes. 
We did not find evidence for the optimal magnitude and inten-
sity of weight loss. However, our data suggest that a weight 
loss of >7 kg and/or >2 kg per week from either surgery or diet 
results in a beneficial effect on sUA at medium-term/long-term 
follow-up based on three studies27 28 46 and that weight loss 
of >3.5 kg showed beneficial effects on gout attacks at medi-
um-term/long-term follow-up based on six studies.27 28 40 45 46 49 
However, with the present quality of evidence, further research 
may change these findings. WDdtAEs and SAEs were poorly 
reported. At short term, weight loss from bariatric surgery 
showed temporarily increased sUA levels and gout attacks, 
that is, a harmful effect, in the immediate postoperative period 
based on two studies.27 46
It is well known that there is a higher risk of gout attacks 
during the first months of urate-lowering therapy, postsurgery 
and starvation.59 One hypothesis is that dramatic changes in 
sUA, rather than absolute level, triggers gout attacks.60 In line 
with this, a study61 comparing gout patients experiencing post-
operative gout attacks with those who did not, find that the first 
group had higher presurgical sUA and a more rapid and larger 
decrease in sUA 3 days after surgery. Dalbeth et al27 reported a 
drastic increase 2 weeks after surgery, which they suggested was 
due to renal dysfunction associated with major surgery, or meta-
bolic effects from fasting or rapid weight loss (catabolic state), 
Figure 2 Relationship between weight loss and serum uric acid at latest follow-up. Estimates are shown with 95% confidence intervals. sUA, serum 
uric acid.
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and they report one case of postoperative gout attack together 
with severe hyperuricaemia. Other factors increasing sUA levels 
are fasting,62–64 dehydration65 and tissue hypoxia.66 Fasting-as-
sociated increase in sUA is likely due to tissue breakdown.67 68 In 
line with this, daytime fasting during Ramadan, without weight 
loss, compared with non-fasting did not increase sUA or gout 
attacks in gout patients.69
Increased sUA seems to be related to decreased estimated 
glomerular filtration rate (eGFR).70 71 This is probably related 
to sUA affecting blood pressure,72 which may be caused by 
Figure 3 Risk of bias summary figure. Similar outcomes has been put together in the figure but has been assessed separately. *Multiple 
publications existed. A primary publication was chosen. †Potentially serious risk of bias, since physical function was not reported in the article, but 
assessed low since data were provided from the author through email contact. BMI, body mass index; sUA, serum uric acid.
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increased vascular stiffness.73 74 Reducing sUA may therefore 
have beneficial effect on susceptibility towards cardiovascular 
disease and diminished renal function.
In our study, we lacked evidence for many prespecified 
outcomes important to patients. Serum uric acid was among 
the most frequently reported outcomes and is recommended 
as a treatment target,15–19 21–23 since elevated sUA is consid-
ered to cause the disease. Gout attacks in this study is not 
well defined and was reported in various ways and over 
various follow-up times. Therefore, stating fewer gout attacks 
following weight loss is not very specific and not necessarily 
assessable in smaller study sizes, or when attacks were not 
systematically assessed. At least three studies27 43 45 did not 
point at reduced frequency of attacks, of which Friedman 
et al43 did not report any baseline and Perez-Ruiz et al45 did 
show less increase compared with control. Other studies 
can mask increasing number of attacks by reporting number 
of patients experiencing ≥1 attack over various follow-ups. 
Therefore, one could consider rating the evidence for gout 
attacks further down for indirectness.
Limitations of our methods include no independent double 
study selection, data extraction or risk of bias assessment. A 
limitation of investigating weight loss per se is that weight loss 
can be a consequence of many different interventions, that 
is, cointerventions, or conditions. Hence, it was impossible 
to ensure the weight reduction to be the only difference in 
terms of intervention from the comparison group, resulting in 
the inclusion of a wide variety of study settings. This is also 
observed as for which variables have been measured longitu-
dinally. The included cohort studies stratifying according to 
weight loss may include unintentional weight loss for example, 
from illness, which is not relevant as intervention. Adding 
this to the fact that the majority of our included studies did 
not have a comparison group introducing non-controllable 
confounding, we cannot be sure that weight loss is accountable 
for all the effects observed. As a result, the implementation of 
weight loss intervention in clinical practice cannot be speci-
fied from the included studies. Taking the limitations of the 
available evidence into account, one may suggest, in order to 
address the effect of weight loss on sUA, that there currently 
is a need to perform a systematic review and meta-analysis of 
data not only for gout patients.
In conclusion, the available evidence is in favour of weight 
loss for overweight gout patients at medium-term/long-term 
follow-up on sUA, achieving sUA target and gout attacks. 
However, the evidence is of low, moderate and low quality, 
respectively. Harms were poorly reported. However, gout 
attacks might occur at short term when initiating treatment. 
We believe that there is an urgent need to initiate rigorous 
prospective studies (preferably RCTs) to provide more trust-
worthy estimates of gout-related benefits and harms including 
the effect on joint pain, tophi, physical function, HRQoL, 
adverse events and patient global assessment. Future research 
should aim at identifying the optimal magnitude and inten-
sity of weight loss, the preferred method of weight loss, 
including prevention of flare, which cointerventions result in 
a better effect, and which gout patients will benefit the most, 
for example, grouped according to type (and possibly severity) 
of overweight and comorbidities.
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